Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Tomasz M. Beer(Exact Sciences (United States)), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Cora N. Sternberg(Cornell University), Teuvo L.J. Tammela(Tampere University), Anders Bjartell(Lund University), Choung‐Soo Kim(Asan Medical Center), Yohann Loriot(Institut Gustave Roussy), Peter Iversen(University of Copenhagen), Andrew J. Armstrong(Duke University), Go Kimura(Nippon Medical School), Fred Saad(Centre Hospitalier de l’Université de Montréal), Peter F.A. Mulders(Radboud University Nijmegen), Michael Borre(Aarhus University), Suha Sari, Steve van Os(Astellas Pharma (Netherlands)), Teresa Parli, Christopher P. Evans(University of Nevada, Reno), Ad Theeuwes(Astellas Pharma (Netherlands)), Celestia S. Higano(University of British Columbia), Kurt Miller(Charité - Universitätsmedizin Berlin), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center)
European Urology
July 29, 2016
10.1016/j.eururo.2016.07.032
Cited by 414

Related Papers

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k